<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806386</url>
  </required_header>
  <id_info>
    <org_study_id>2021P000691</org_study_id>
    <nct_id>NCT04806386</nct_id>
  </id_info>
  <brief_title>The Role of Fiber in the Prevention and Treatment of Fecal Incontinence</brief_title>
  <official_title>The Role of Fiber in the Prevention and Treatment of Fecal Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of fiber supplementation on the fecal&#xD;
      metagenome and metabolome in relation to symptoms and anorectal physiology in post-menopausal&#xD;
      women with irritable bowel syndrome with diarrhea suffering from liquid stool fecal&#xD;
      incontinence (FI.)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single-arm study at Massachusetts General Hospital that aims to&#xD;
      recruit post-menopausal female patients with solid stool fecal incontinence. The&#xD;
      investigators hope that subjects taking a daily fiber supplement will experience reduced&#xD;
      episodes and symptoms of fecal incontinence, measured through quality of life questionnaires&#xD;
      and daily stool and food diaries. Subjects will undergo 2 anorectal manometry procedures.&#xD;
      Stool samples will also be collected for metabolomic and metagenomic analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2021</start_date>
  <completion_date type="Anticipated">August 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stool metagenomics</measure>
    <time_frame>Change from baseline to final visit. Through study completion, up to 6 weeks.</time_frame>
    <description>Sequence-based microbial community surveys will be carried out to characterize rare taxa and understand relationships between community membership and function from stool samples collected from baseline to the final visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stool microbiome</measure>
    <time_frame>Change from baseline to final visit. Through study completion, up to 6 weeks.</time_frame>
    <description>Stool samples will be shipped to Metabolon Inc, for metabolomics profiling on a well-validated high-throughput metabolomics platform. Sample prep and global metabolomics profiling will be conducted using four liquid chromatography tandem mass spectrometry methods that measure four complementary sets of metabolite classes. Metabolite peaks are quantified using area-under-the curve. Raw area counts for each metabolite in each sample are normalized to correct for variation resulting from inter-day tuning differences by setting the medians to 1.0 for each run. Metabolites are identified by automated comparison of the ion features in the experimental samples to a reference library of ~8,000 chemical standard entries that are curated for quality control using Metabolon software. Coefficients of variations (CVs) will be measured in blinded quality control samples randomly distributed among study samples, and we will analyze and control for batch variation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fecal incontinence severity index (FISI)</measure>
    <time_frame>Change from baseline to final visit. Through study completion, up to 6 weeks.</time_frame>
    <description>Questionnaire about the severity of symptoms in those with fecal incontinence. Consists of 4 questions, each rated on a scale of 1 to 6. Lower scores indicate higher severity of symptoms. (Min, 4, max 24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal Incontinence quality of life (FIQL)</measure>
    <time_frame>Change from baseline to final visit. Through study completion, up to 6 weeks.</time_frame>
    <description>Questionnaire about the quality of life of those with fecal incontinence. Questions are rated from 1 to 4 in each section. Lower rating represent worse quality of life. Subscales exist for lifestyle, coping behavior, embarrassment, and depression. There is no total score for this outcome, only subscores per section. (Min 4, max, 16)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anorectal manometry parameters</measure>
    <time_frame>Change from baseline to final visit. Through study completion, up to 6 weeks.</time_frame>
    <description>Anorectal manometry (ARM) procedure performed to measure the change in anal and rectal muscle function and sensation at baseline and at the final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Translumbosacral anorectal magnetic stimulation</measure>
    <time_frame>Change from baseline to final visit. Through study completion, up to 6 weeks.</time_frame>
    <description>Translumbosacral anorectal magnetic stimulation (TAMS) performed during the ARM procedure to measure the change in the nerve conduction between the spinal cord and rectum at baseline and at the final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of relief</measure>
    <time_frame>Change from baseline to final visit. Through study completion, up to 6 weeks.</time_frame>
    <description>A 7-point scale indicating overall fecal incontinence symptom relief where 1 represents completely relieved and 7 represents completely worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bloating scale</measure>
    <time_frame>Change from baseline to final visit. Through study completion, up to 6 weeks.</time_frame>
    <description>A 10-point scale indicating bloating severity where 0 represents the least severity and 10 represents the most severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgency scale</measure>
    <time_frame>Change from baseline to final visit. Through study completion, up to 6 weeks.</time_frame>
    <description>A 10-point scale indicating urgency severity where 0 represents the least severity and 10 represents the most severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flatus scale</measure>
    <time_frame>Change from baseline to final visit. Through study completion, up to 6 weeks.</time_frame>
    <description>A 10-point scale indicating flatus severity where 0 represents the least severity and 10 represents the most severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference measurement (cm)</measure>
    <time_frame>Change from baseline to final visit. Through study completion, up to 6 weeks.</time_frame>
    <description>A measure of the subject's waist circumference in the area where the most bloating is experienced</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Fecal Incontinence</condition>
  <condition>Irritable Bowel Syndrome With Diarrhea</condition>
  <arm_group>
    <arm_group_label>Psyllium fiber supplement treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive psyllium fiber in the form of edible bars, 7g, twice a day to total 14g per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Psyllium</intervention_name>
    <description>Psyllium fiber powder baked into a bar is commonly used as a first line of treatment for patients with fecal incontinence.</description>
    <arm_group_label>Psyllium fiber supplement treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female, post-menopausal&#xD;
&#xD;
          2. Age 55-85 years old&#xD;
&#xD;
          3. BMI &gt;18.5 and &lt;40 kg/m2&#xD;
&#xD;
          4. Rome IV criteria for liquid stool fecal incontinence occurring at least once per week&#xD;
&#xD;
          5. At least weekly FI episodes during the run-in period&#xD;
&#xD;
          6. Compliant with reporting during run-in (completion of two 7-day bowel diaries)&#xD;
&#xD;
          7. Submission of two stool samples during the run-in period&#xD;
&#xD;
          8. Ability to follow verbal and written instructions&#xD;
&#xD;
          9. Informed consent form signed by the subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Less than one episode per week of liquid stool fecal incontinence&#xD;
&#xD;
          2. Non-compliance with reporting during run-in&#xD;
&#xD;
          3. Patients reporting laxative, enema, and/or suppository usage during the run-in period&#xD;
&#xD;
          4. GI tract structural abnormality that would increase likelihood of obstruction&#xD;
&#xD;
          5. Dysphagia, swallowing disorder, or history of esophageal structural lesions&#xD;
&#xD;
          6. History of GI lumen surgery within 60 days prior to entry into the study&#xD;
&#xD;
          7. Neurological disorders, metabolic disorders, or other significant disease that would&#xD;
             impair their ability to participate in the study&#xD;
&#xD;
          8. Inability to tolerate or contraindication to performance of anorectal manometry&#xD;
&#xD;
          9. Celiac disease, cancer, Crohn's disease, ulcerative colitis&#xD;
&#xD;
         10. Current anorectal fistula and/or abscess&#xD;
&#xD;
         11. Age &lt;55 or &gt;85&#xD;
&#xD;
         12. BMI of &lt;18.5 or â‰¥40 kg/m2&#xD;
&#xD;
         13. History of allergic reaction to psyllium&#xD;
&#xD;
         14. Previous trial of soluble fiber supplementation for fecal incontinence within the&#xD;
             previous 60 days&#xD;
&#xD;
         15. History of sacral nerve stimulator or artificial anal sphincter placement&#xD;
&#xD;
         16. Administration of investigational products within 1 month prior to Screening Visit&#xD;
&#xD;
         17. Subjects anticipating surgical intervention during the study&#xD;
&#xD;
         18. Angina, coronary bypass, or myocardial infarction within 6 months prior to Screening&#xD;
             Visit&#xD;
&#xD;
         19. History of intestinal stricture (e.g., Crohn's disease)&#xD;
&#xD;
         20. History of intestinal obstruction or subjects at high risk of intestinal obstruction&#xD;
             including suspected small bowel adhesions&#xD;
&#xD;
         21. History of malabsorption&#xD;
&#xD;
         22. Any other clinically significant disease interfering with the assessments of psyllium,&#xD;
             according to the Investigator (e.g., disease requiring corrective treatment,&#xD;
             potentially leading to study discontinuation)&#xD;
&#xD;
         23. Any relevant biochemical abnormality interfering with the assessments of psyllium,&#xD;
             according to the Investigator&#xD;
&#xD;
         24. Patients with metallic implants within a 30 cm radius of the TAMS electromagnetic coil&#xD;
&#xD;
         25. Currently on opioids&#xD;
&#xD;
         26. Patients with severe cardiac disease, chronic renal failure, or previous GI surgery&#xD;
             EXCEPT cholecystectomy, appendectomy, Nissen fundoplication, and partial colectomy&#xD;
&#xD;
         27. Patients with neurological diseases and increased intracranial pressure&#xD;
&#xD;
         28. Patients with impaired cognizance&#xD;
&#xD;
         29. Previous pelvic surgery/radiation, radical hysterectomy&#xD;
&#xD;
         30. Patients with Ulcerative Colitis or Crohn's Disease&#xD;
&#xD;
         31. History of or current rectal prolapse&#xD;
&#xD;
         32. Previous history of anal fissure, anal surgery (abscess), congenital anorectal&#xD;
             malformation, fistulae or inflamed hemorrhoids&#xD;
&#xD;
         33. Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyle Staller, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyle Staller, MD MPH</last_name>
    <phone>617-724-6038</phone>
    <email>kstaller@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Braden Kuo, MD</last_name>
    <phone>617-726-5525</phone>
    <email>bkuo@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mimi Paz</last_name>
      <phone>617-643-5742</phone>
      <email>mpaz3@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Kyle Staller, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Braden Kuo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Kyle Staller, MD, MPH</investigator_full_name>
    <investigator_title>Assistant Professor in Medicine</investigator_title>
  </responsible_party>
  <keyword>IBS-D</keyword>
  <keyword>IBS</keyword>
  <keyword>FI</keyword>
  <keyword>Fecal Incontinence</keyword>
  <keyword>Irritable Bowel Syndrome with Diarrhea</keyword>
  <keyword>Irritable Bowel Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Fecal Incontinence</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psyllium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

